Clarinol (Conjugated Linoleic Acid)

Clarinol is a patented, safflower oil-derived form of conjugated linoleic acid (CLA) standardized to approximately 80% active CLA isomers, primarily c9,t11 and t10,c12. The t10,c12 isomer is considered the principal bioactive form thought to influence fat cell metabolism and lean body mass, though clinical evidence for meaningful weight management outcomes remains limited.

Origin & History

Clarinol is a branded form of conjugated linoleic acid (CLA), naturally occurring at low levels in ruminant meat and dairy products as the cis-9,trans-11 isomer. Commercially synthesized from plant oils (safflower, soybean, sesame) via alkaline isomerization at high temperatures (180°C) using KOH or NaOH, achieving up to 96% conversion rates.

Historical & Cultural Context

No historical or traditional medicinal uses of CLA or Clarinol are documented in the research. CLA is noted only as a modern synthetic compound or natural ruminant-derived substance without connections to traditional medicine systems.

Health Benefits

• No clinical health benefits documented in the provided research dossier
• Research focuses solely on synthesis methods rather than efficacy data
• No human trials or meta-analyses on body composition effects available
• No evidence provided for lipid metabolism or weight management claims
• Safety and efficacy data absent from current research compilation

How It Works

The t10,c12 CLA isomer found in Clarinol is proposed to inhibit lipoprotein lipase (LPL), an enzyme responsible for facilitating fatty acid uptake into adipocytes, thereby reducing fat accumulation. It may also activate PPARγ (peroxisome proliferator-activated receptor gamma), influencing adipocyte differentiation and lipid oxidation pathways. Additionally, t10,c12 CLA has been studied for potential effects on carnitine palmitoyltransferase (CPT-1) activity, which governs mitochondrial fatty acid beta-oxidation.

Scientific Research

The research dossier contains no human clinical trials, RCTs, or meta-analyses for Clarinol or CLA. No PubMed PMIDs or study details on design, sample size, or health outcomes are provided in the available sources.

Clinical Summary

Available research on Clarinol-branded CLA is heavily weighted toward synthesis characterization and manufacturing methodology rather than controlled human efficacy trials. Broader CLA literature includes randomized controlled trials suggesting modest reductions in body fat mass (approximately 0.05–0.1 kg per week) at doses of 3.2–6.4 g/day, though effect sizes are generally considered clinically modest. Meta-analyses of mixed CLA isomers show inconsistent results across populations, with outcomes varying by isomer ratio, diet, and baseline body composition. No large-scale, long-term human trials specific to the Clarinol formulation with quantified body composition endpoints are currently available in the public literature.

Nutritional Profile

Clarinol is a commercially standardized form of Conjugated Linoleic Acid (CLA) derived from safflower oil (Carthamus tinctorius) via alkaline isomerization. It is classified as a fatty acid supplement, not a whole food, and therefore contains no meaningful vitamins, minerals, fiber, or protein. Macronutrient composition: fat constitutes ~100% of caloric content at approximately 9 kcal/g. The active bioactive compounds are geometric and positional isomers of linoleic acid (C18:2), with Clarinol standardized to contain a minimum of 80% total CLA isomers. The two primary isomers are c9,t11-CLA (rumenic acid, typically ~40% of total CLA content) and t10,c12-CLA (typically ~40% of total CLA content), with the remaining ~20% comprising other minor CLA isomers and unconjugated linoleic acid. Typical commercial dosage forms deliver 1–3.4 g CLA per serving. Bioavailability: CLA isomers are absorbed via the small intestine through standard fatty acid absorption pathways (micelle formation, chylomicron packaging); absorption efficiency is estimated at 90–95% under fed conditions. The t10,c12 isomer is the subject of most mechanistic research regarding lipid metabolism, while c9,t11 is the predominant naturally occurring dietary isomer found in ruminant-derived foods. No synergistic micronutrients are present in the isolated ingredient.

Preparation & Dosage

No clinically studied dosage ranges for Clarinol or CLA are detailed in the available research. Standardization percentages and human trial dosing information are not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to determine synergistic ingredients

Safety & Interactions

CLA supplementation, including Clarinol, has been associated with gastrointestinal side effects such as nausea, diarrhea, and stomach upset, particularly at doses above 3.4 g/day. The t10,c12 isomer has raised concerns in some studies regarding potential worsening of insulin sensitivity and lipid oxidative stress markers in certain populations, including overweight or insulin-resistant individuals. Clarinol may interact with anticoagulant medications such as warfarin due to its fatty acid composition influencing platelet aggregation pathways. Pregnant and breastfeeding women should avoid CLA supplementation due to insufficient safety data for these populations.